Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Daily Feed
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Energy
    • Robotics
    • Bio & Healthcare
  • Toggle search form

[Disclosure] Samsung Biologics (207940) Sets Dec 31 as Record Date to Confirm Shareholders for 14th Annual General Meeting

Posted on December 16, 2024July 13, 2026 By K-STOCK Editor No Comments on [Disclosure] Samsung Biologics (207940) Sets Dec 31 as Record Date to Confirm Shareholders for 14th Annual General Meeting

Source Fact: Financial Supervisory Service DART / 2024-12-16

Disclosure Type: Setting of Record Date or Period for Closing Shareholders’ Register

💡 3-Second Summary

Samsung Biologics has set December 31, 2024, as the ‘Record Date’ to officially finalize the list of eligible shareholders who can exercise their voting rights at the upcoming Annual General Meeting (AGM) early next year.

📊 1. [Summary of Core Disclosure & Key Figures]

  • Record Date: December 31, 2024
  • Period for Closing Register: January 1, 2025 ~ January 31, 2025
  • Purpose/Reason: Finalization of eligible shareholders for holding the 14th Annual General Meeting (AGM)
  • Key Conditions: Investors who wish to exercise their voting rights at the upcoming AGM must hold Samsung Biologics shares and be registered in the shareholder list as of December 31, 2024. Alterations to the shareholder register (transfer of shares) will be temporarily suspended during January 2025.

📈 2. [Expert Insight: Implications for Investors]

  • Routine Corporate Governance Procedure: This disclosure represents a standard, mandated corporate procedure implemented at the end of every fiscal year. It does not indicate any immediate changes to the company’s financial status or operational Fundamental.
  • Investor Consideration: To participate and vote in the upcoming general meeting, investors must ensure their names are listed on the register by the December 31 deadline. However, considering the Korean stock market’s settlement system (T+2 basis) and year-end market holidays, market participants need to independently verify the actual final trading day required for registration. Since this event does not impact corporate valuation, investors are advised to focus on the subsequent official AGM convocation notices to analyze the specific agendas and resolutions proposed.

📝 Editor’s Comment (by K-STOCK Editor)

Applied Comment Style: 진지형 (Cautionary View)

This is the very first whistle signaling the approach of the annual general meeting season. While it might appear to be a simple, dry administrative process, it holds structural importance as it defines who gets a voice in the company’s future. For global investors looking to secure their voting rights, meticulous attention must be paid to the calendar. Due to the Korean market’s T+2 settlement cycle and year-end book-closing schedules, buying on the record date itself will not suffice. It is a prudent time to double-check execution timelines while awaiting the concrete corporate agendas to be unveiled in the upcoming AGM convocation.

📢 Disclaimer & Source Information

Source: This content was structured and newly generated based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).

Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.

Contact: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] LEENO Industrial (058470) Sets December 31 as Record Date for Shareholder Registry Closure to Finalize Voting and Dividend Rights
Next Post: [Disclosure] SK hynix (000660) Dividend Framework Overhaul: Holding Shares on Dec 31 Will NOT Guarantee Year-End Payout

Related Posts

[Disclosure] Samsung Biologics (207940) Approves Corporate Split Plan at Extraordinary General Meeting of Shareholders Disclosures
[Disclosure] SK Hynix (000660) Subsidiary ‘Solidigm Inc.’ Decides on 14.7 Trillion KRW Capital Increase for Business Acquisition Semiconductors
[Disclosure] Samsung Biologics(207940) Raises 2025 Annual Revenue Guidance to KRW 5.8T (Fair Disclosure) Disclosures
[Disclosure] Alteogen (196170) to Host Investor Relations (IR) Conference for Major Overseas Institutional Investors Disclosures
[Disclosure] Samsung Biologics (207940) Stock Futures and Options to Be Suspended from Trading Starting October 30 Due to Underlying Asset Halt Disclosures
[Disclosure] Samsung Biologics (207940) Reclassifies Sub-Industry Category Name to ‘Manufacture of Basic Pharmaceutical Products’ per Regulatory Amendments Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] SK square(402340), Subsidiary SK hynix Finalizes KRW 40T Paid-in Capital Increase with 2.72% PremiumJuly 10, 2026
  • [Disclosure] SK square(402340), Subsidiary SK hynix Finalizes Nasdaq Listing and 177.9M ADR Issuance VolumeJuly 10, 2026
  • [Disclosure] SK square(402340), Subsidiary SK hynix Confirms Nasdaq Listing and KRW 40T ADR Issuance TermsJuly 10, 2026
  • [Disclosure] SK Hynix(000660) Finalizes Terms for KRW 40 Trillion Paid-in Capital Increase Linked to Nasdaq ADRs (Issued at 2.72% Premium)July 10, 2026
  • [Disclosure] SK Hynix(000660) Finalizes Pricing and Timeline Terms for US Nasdaq ADR Issuance and Overseas ListingJuly 10, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme